Skip to main content

Novel Cardioprotective Antidiabetic Medications

New Content ItemThe thematic series focusses on two groups of antidiabetic medications that have demonstrated cardiovascular benefits with consistently reduced major adverse cardiac events, improvement in heart failure and diminished cardiovascular and all-cause mortality. Namely, these are the sodium-glucose cotransporter-2 inhibitors (SGLT2i, also called gliflozins) and the glucagon-like peptide-1 receptor agonists (GLP-1a, also called incretin mimetics).
Due to their cardioprotective effect, these compounds, as well as the GLP-1a "cousin" tirzepatide, represent a real breakthrough in antidiabetic therapeutics. Repurposing antidiabetic drugs for the treatment of cardiovascular diseases is a trend that may increase in a near future allowing the inclusion of new drugs when their underlying molecular mechanisms of action will be unveiled. 

We encourage submissions of research as well as review articles. 
 

  1. Glucokinase activators (GKAs) are an emerging class of glucose lowering drugs that activate the glucose-sensing enzyme glucokinase (GK). Pending formal cardiovascular outcome trials, we applied two-sample Mend...

    Authors: Ke Wang, Mai Shi, Chuiguo Huang, Baoqi Fan, Andrea O. Y. Luk, Alice P. S. Kong, Ronald C. W. Ma, Juliana C. N. Chan and Elaine Chow
    Citation: Cardiovascular Diabetology 2022 21:192
  2. Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and ...

    Authors: Michael A. Nauck and David A. D‘Alessio
    Citation: Cardiovascular Diabetology 2022 21:169
  3. Incretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polyp...

    Authors: Enrique Z. Fisman and Alexander Tenenbaum
    Citation: Cardiovascular Diabetology 2021 20:225